{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000593","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-05-13T11:01:04+00:00","discovered_at":"2026-05-13T11:05:00.322441+00:00","generated_at":"2026-05-13T11:10:08.451849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026","bullets":["Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.","Closed $200M private placement (up to $400M) in Feb 2026; cash $186.6M funds into late 2027.","Appointed Michael Panzara, M.D., as CMO; initiated CEO search with commercial neurology expertise.","Phase 3 ENSURE RMS top-line data expected by end 2026; NDA submission planned mid-2027.","Key European patent granted for vidofludimus calcium with potential exclusivity into 2043."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000593","json":"https://secwatch.observer/filing/0001193805-26-000593.json","markdown":"https://secwatch.observer/filing/0001193805-26-000593.md","text":"https://secwatch.observer/filing/0001193805-26-000593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/0001193805-26-000593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/e665461_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:10:08.451849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"606a05bf2f2f6aa9de711c084616700d322a8d5e","claim":"IMMUNIC, INC. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 13 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended March 31, 2026, and providing a corporate update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/0001193805-26-000593-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}